Response Genetics, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
2009-09-08 18:43:02 -
Response Genetics, Inc. (Nasdaq:RGDX) announced today that its president and CEO, Kathleen Danenberg, will present at the Rodman & Renshaw 11th Annual Healthcare Conference at 5:20 p.m. on Thursday, September 10. The conference is being held at the New York Palace Hotel.
The presentation will be made available by webcast and can be accessed at www.wsw.com/webcast/rrshq15/rgdx : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
About Response
Genetics, Inc.
Response Genetics, Inc. (“RGI”) (the “Company”) (Nasdaq:RGDX) is focused on the development and sale of molecular diagnostic tests for cancer.
RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, RGI generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com :
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as defining, targeting and individualizing therapies for cancer patients, the ability of the Company to continue to ramp sales of its tests and to continue to expand its test panels, BRAF mutation analysis having predictive value, VEGFR2 gene expression as a predictive biomarker, EGFR mutation analyses as a determinant of sensitivity to TKI, TS as a predictive biomarker for personalizing therapy, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.
These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
Trout GroupPeter Rahmer, 646-272-8526 (Investor Relations)orFleishman-HillardBarry
Sudbeck, 415-318-4261 (Media Relations)
